CD34 and myeloproliferative disorder: Due to the paucity of CD34+ samples in patients with JAK2V617F+ ET, we integrated the samples of JAK2V617F+ PV and JAK2V617F+ ET into one group named JAK2V617F+ PV/ET, reflecting the chronic and indolent stage of MPN.